Skip to content

AI discovers 160,000 new virus species

Using artificial intelligence (AI), details of a diverse and fundamental branch of life that lives directly beneath our feet and in every corner of the Earth have been brought to light. Using a machine learning tool, 161,979 new species of RNA viruses were discovered. Researchers are convinced that this tool could significantly improve the mapping of life on Earth and contribute to the identification of many more millions of viruses that still need to be characterized. The study, published in Cell and conducted by an international research team, is the most extensive work on the discovery of virus species ever published. "We have been opened a window to an otherwise hidden part of life on Earth, revealing remarkable biodiversity," said the lead author of the study, Professor Edwards Holmes of the School of Medical Sciences at the University of Sydney's Faculty of Medicine and Health. Although RNA viruses are often associated with... 

more »AI discovers 160,000 new virus species

IVDR is burdening laboratory medicine

The IVDR has far-reaching implications for laboratory medicine in Europe. Here are the most important concrete effects based on the available data and facts: The IVDR leads to a significant expansion of the scope for in vitro diagnostics (IVDs). For the first time, laboratory-developed tests (so-called in-house IVDs or Laboratory Developed Tests, LDTs) are also regulated. Studies show that up to 75% of the tests used in specialized laboratories are in-house IVDs[1][5]. These must now meet the requirements of the IVDR. A central point is the introduction of a risk-based classification system for IVDs into four risk classes. As a result, significantly more products (approx. 80-90%) must be tested by a notified body[2]. This leads to higher costs and longer development times for new tests. Laboratories must implement a quality management system according to ISO 15189 for in-house IVDs. A survey by BioMed Alliance showed that the proportion of ISO 15189-compliant laboratories will increase from 77% to 88%[5]. This means a... 

more »IVDR is burdening laboratory medicine

Why MedLabPortal.de is worth reading

  • News

MedLabPortal.de ist das Informationsportal der DGKL und hat sich als unverzichtbare Informationsquelle für Fachleute und Interessierte im Bereich der Labormedizin etabliert. Die Plattform bietet einen umfassenden Einblick in die neuesten Entwicklungen, Forschungsergebnisse und Trends der Branche[3]. Durch tägliche Aktualisierungen bleiben Leser stets auf dem neuesten Stand der schnelllebigen Welt der Medizin und Labordiagnostik[3]. Die Bandbreite der behandelten Themen ist beeindruckend: Von bahnbrechenden Forschungsergebnissen wie dem Mitochondrientransfer zur Stärkung der Krebsimmuntherapie bis hin zu gesundheitspolitischen Diskussionen wird ein breites Spektrum abgedeckt[3]. Ein besonderer Fokus liegt auf der Digitalisierung im Gesundheitswesen. MedLabPortal.de beleuchtet kritisch und informativ Themen wie die elektronische Patientenakte (ePA) und Medizinische Informationsobjekte (MIO), die die Zukunft der medizinischen Versorgung maßgeblich beeinflussen werden[1]. Auch innovative Technologien wie Blockchain und künstliche Intelligenz und deren Potenzial, die Labormedizin zu revolutionieren, werden ausführlich diskutiert[2][6]. Die Plattform bietet nicht nur Nachrichten, sondern auch tiefgehende… 

more »Warum MedLabPortal.de lesenswert ist

Life Sciences: Collaboration between the United States and China in decline

The collaboration between the United States and China in the life sciences has been a significant driver of scientific progress over the past few decades. However, recent geopolitical tensions and policy changes have begun to impact this crucial partnership. Historical Context The U.S.-China Science and Technology Agreement (STA), first signed in 1979, laid the foundation for scientific cooperation between the two nations[4]. Initially focused on agricultural research, the agreement expanded over time to encompass a broader range of scientific fields, including the life sciences. This collaboration has been instrumental in fostering groundbreaking research and innovations in areas such as agriculture, clean energy, public health, and the environment[2] Collaboration Trends For many years, China has been the United States‘ most important collaborator in the life sciences. Since 2013, China has held this top position[1]. The partnership has led to a rapid… 

more »Life Sciences: Collaboration between the United States and China in decline

Advancements in Space Omics

Recent advancements in space omics have ushered in a new era of understanding how spaceflight affects human physiology and biology. The Space Omics and Medical Atlas (SOMA), released in 2024, represents a significant milestone in this field, providing the largest-ever collection of data for aerospace medicine and space biology[2]. SOMA encompasses data from various missions, including the NASA Twins Study, JAXA CFE study, SpaceX Inspiration4 crew, Axiom, and Polaris[4]. This comprehensive resource has led to a more than tenfold increase in publicly available human space omics data, offering unprecedented insights into the molecular and physiological changes that occur during spaceflight[4]. The SOMA package includes 44 publications, with 32 featuring at least one member of the Ames Space Biosciences Division team[2]. This collaborative effort involved over 100 institutions from more than 25 countries, highlighting the global nature of space research[2]. One… 

more »Advancements in Space Omics

MHH: Hospital of maximum care wants to strike

Despite ongoing negotiations regarding relief measures for employees at the Hannover Medical School (MHH), the Verdi union has called its members to a three-day warning strike next week. The strike is scheduled to take place from Wednesday, October 16, 2024, to Friday, October 18, 2024, inclusive. Emergencies will be adequately treated even on strike days. To this end, the MHH has concluded an emergency service agreement with Verdi. However, considerable restrictions may again occur in daily hospital operations on the strike days. This particularly affects planned surgeries, planned inpatient admissions, and outpatient treatments. To avert longer-term restrictions in operating rooms, wards, and outpatient clinics, and their consequences, the legality of the now announced strike is to be clarified by the courts. During a three-day warning strike in September, hundreds of surgeries and treatments had to be postponed or canceled. A planned three-day work stoppage that Verdi planned in August… 

more »MHH: Hospital providing maximum care plans to strike

Liquid biopsy shows amount of tumor DNA in blood

Parallel to staging diagnostics, researchers from Tübingen therefore conducted a study monitoring a new method, the so-called liquid biopsy – a blood test that can be used to detect and analyze circulating tumor DNA in the body. Liquid biopsies are already routinely performed for breast and lung cancer. For malignant melanoma, liquid biopsies are currently only used in individual cases and are not reimbursed by statutory health insurance companies in routine care. However, liquid biopsies are becoming increasingly relevant. "In contrast to PET-CT, it is significantly more cost-effective and can be repeated multiple times in a short period, for example, monthly. Just a few weeks after starting therapy with ICI, the test shows whether the amount of tumor DNA in the blood is decreasing or increasing," explains Prof. Dr. Andrea Forschner, head of the Melanoma Clinic at the University Dermatology Clinic in Tübingen. Together with Dr. Christopher Schroeder from the Institute for Medical Genetics and...

more »Liquid biopsy shows amount of tumor DNA in blood

Why should one read labnews.ai?

  • News

A comprehensive comparison with other websites. labnews.ai/ (LabNews) stands out as a valuable resource for professionals and enthusiasts in the life sciences, biotechnology, and digital health sectors. This US website in German and English offers several compelling reasons to make it a regular part of one's reading routine, especially when compared to other popular biotech news sources. Firstly, labnews.ai/ provides a focused and specialized approach to news coverage. Unlike broader platforms like BioSpace or FierceBiotech, which cover a wide range of biotech and pharmaceutical topics, labnews.ai/ concentrates specifically on laboratory sciences, offering in-depth insights into this crucial area of the life sciences industry[1]. This specialization allows readers to access more targeted and relevant information for those working directly in laboratory settings or closely related fields. The website's commitment to delivering current news and developments is another key advantage. labnews.ai/ keeps…

more »Why should one read labnews.ai?

Intelligent bioroboter to treat prostate cancer

The US Food and Drug Administration (FDA) has granted medical technology company PROCEPT BioRobotics approval to conduct a clinical trial for the treatment of prostate cancer using its AquaBeam Robotic System[1]. This decision marks an important step in the development of new therapeutic options for prostate cancer patients. Innovative technology against a common type of cancer Prostate cancer is the most common cancer in men in Germany. Approximately 65,000 new cases are diagnosed annually[2]. The disease originates from the glandular tissue of the prostate and often remains asymptomatic in its early stages[2]. Risk factors include advanced age and a family history of the disease[4]. PROCEPT BioRobotics' AquaBeam Robotic System uses a combination of imaging, robot-assisted control, and waterjet ablation. This technology enables precise and gentle removal of prostate tissue. Hope for improved treatment options The now-approved study will investigate the efficacy and safety of the system in treating early-stage prostate cancer. Dr. Nikolai Aljuri, founder and CEO… 

more »Intelligent bioroboter to treat prostate cancer

FDA Reports Surge in AI/ML-Enabled Medical Devices

The U.S. Food and Drug Administration (FDA) has announced a significant milestone in the field of artificial intelligence and machine learning (AI/ML) in healthcare. As of August 7, 2024, the agency has authorized a total of 950 AI/ML-enabled medical devices for use in the United States. This remarkable figure underscores the rapid advancement and adoption of AI technologies in the medical field. The FDA has been diligently tracking and evaluating these innovative devices, which span across various medical disciplines. To provide transparency and inform the public, the FDA has compiled a comprehensive list of these authorized AI/ML-enabled devices. This list, which is regularly updated, includes detailed information such as the device name, manufacturer, date of approval, and its primary intended use. The FDA emphasizes that all listed devices have undergone rigorous evaluation to ensure they meet the agency’s stringent safety… 

more »FDA Reports Surge in AI/ML-Enabled Medical Devices